Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data

The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.

Gilead and Kite at ASCO 2023 • Source: Alaric DeArment

Gilead Sciences, Inc., through its Kite Pharma subsidiary, has taken the lead in the CD19-directed CAR-T cell therapy market with Yescarta (axicabtagene ciloleucel), a position that appears to be reinforced by new, longer-term data in large B-cell lymphoma (LBCL) that were presented at the American Society of Clinical Oncology meeting.

Kite reported results from the Phase III ZUMA-7 clinical trial of Yescarta at ASCO on 5 June. The study tested...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from ASCO

More from Conferences